title: Hyponatraemia: more than just a marker of disease severity?
abstract: Hyponatraemia--the most common serum electrolyte disorder--has also emerged as an important marker of the severity and prognosis of important diseases such as heart failure and cirrhosis. Acute hyponatraemia can cause severe encephalopathy, but the rapid correction of chronic hyponatraemia can also profoundly impair brain function and even cause death. With the expanding elderly population and the increased prevalence of hyponatraemia in this segment of society, prospective studies are needed to examine whether correcting hyponatraemia in the elderly will diminish cognitive impairment, improve balance and reduce the incidence of falls and fractures. Given that polypharmacy is also common in the elderly population, the various medications that may stimulate arginine vasopressin release and/or enhance the hormone's action to increase water absorption must also be taken into consideration. Whether hyponatraemia in a patient with cancer is merely a marker of poor prognosis or whether its presence may alter the patient's quality of life remains to be examined. In any case, hyponatraemia can no longer be considered as just a biochemical bystander in the ill patient. A systematic diagnostic approach is necessary to determine the specific aetiology of a patient's hyponatraemia. Therapy must then be dictated not only by recognized reversible causes such as advanced hypothyroidism, adrenal insufficiency, diuretics or other medicines, but also by whether the hyponatraemia occurred acutely or chronically. Information is emerging that the vast majority of cases of hyponatraemia are caused by the nonosmotic release of arginine vasopressin. Now that vasopressin V2-receptor blockers are available, a new era of clinical investigation is necessary to examine whether hyponatraemia is just a marker of severe disease or whether correction of hyponatraemia could improve a patient's quality of life. Such an approach must involve prospective randomized studies in different groups of patients with hyponatraemia, including those with advanced heart failure, those with cirrhosis, patients with cancer, and the elderly.
authors.affiliation: University of Colorado School of Medicine, 12700 East 19th Avenue C281, Aurora, CO 80045, USA. robert.schrier@ucdenver.edu
authors.forename: Robert W
authors.initials: RW
authors.lastname: Schrier
authors.forename: Shailendra
authors.initials: S
authors.lastname: Sharma
authors.forename: Dmitry
authors.initials: D
authors.lastname: Shchekochikhin
mesh_terms: D006333:Heart Failure / Q000150:complications; D006801:Humans; D007010:Hyponatremia / Q000209:etiology / Q000628:therapy; D007177:Inappropriate ADH Syndrome / Q000150:complications; D008103:Liver Cirrhosis / Q000150:complications; D012720:Severity of Illness Index